| Style | Citing Format |
|---|---|
| MLA | G, et al.. "Investigation the Effects of Rivaroxaban on Oxidative Stress and Antioxidant Capacity in Patients Heart Failure." ARYA Atherosclerosis, vol. 21, no. 4, 2025, pp. 36-43. |
| APA | G, Sichani ZR, Nayeri H, Asgary S (2025). Investigation the Effects of Rivaroxaban on Oxidative Stress and Antioxidant Capacity in Patients Heart Failure. ARYA Atherosclerosis, 21(4), 36-43. |
| Chicago | G, Sichani ZR, Nayeri H, Asgary S. "Investigation the Effects of Rivaroxaban on Oxidative Stress and Antioxidant Capacity in Patients Heart Failure." ARYA Atherosclerosis 21, no. 4 (2025): 36-43. |
| Harvard | G et al. (2025) 'Investigation the Effects of Rivaroxaban on Oxidative Stress and Antioxidant Capacity in Patients Heart Failure', ARYA Atherosclerosis, 21(4), pp. 36-43. |
| Vancouver | G, Sichani ZR, Nayeri H, Asgary S. Investigation the Effects of Rivaroxaban on Oxidative Stress and Antioxidant Capacity in Patients Heart Failure. ARYA Atherosclerosis. 2025;21(4):36-43. |
| BibTex | @article{ author = { G and Sichani ZR and Nayeri H and Asgary S}, title = {Investigation the Effects of Rivaroxaban on Oxidative Stress and Antioxidant Capacity in Patients Heart Failure}, journal = {ARYA Atherosclerosis}, volume = {21}, number = {4}, pages = {36-43}, year = {2025} } |
| RIS | TY - JOUR AU - G AU - Sichani ZR AU - Nayeri H AU - Asgary S TI - Investigation the Effects of Rivaroxaban on Oxidative Stress and Antioxidant Capacity in Patients Heart Failure JO - ARYA Atherosclerosis VL - 21 IS - 4 SP - 36 EP - 43 PY - 2025 ER - |